Stocktoria
IDEXX LABORATORIES INC /DE IDXX
IDEXX LABORATORIES INC /DE (IDXX) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $4.3B at a 24.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.53 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-11 | Barclays | Overweight (main) |
| 2026-08-05 | UBS | Neutral (main) |
| 2026-08-05 | Citigroup | Neutral (main) |
| 2026-07-27 | UBS | Neutral (main) |
| 2026-04-28 | UBS | Neutral (main) |
| 2026-04-15 | Citigroup | Neutral (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.079 |
| Retained earnings / assets | 1.908 |
| EBIT / assets | 0.406 |
| Equity / liabilities | 0.92 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | 8/9 | 10.43 | 41.1 | +10.4% |
| QDEL | QuidelOrtho Corp | 5/9 | -0.56 | — | -1.9% |
| LNTH | Lantheus Holdings, Inc. | 4/9 | 4.61 | 30.6 | +0.5% |
| NEOG | NEOGEN CORP | 4/9 | -0.23 | — | -2.7% |
| MYGN | MYRIAD GENETICS INC | 5/9 | -5.88 | — | -1.6% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
About IDEXX LABORATORIES INC /DE
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
FAQ
Is IDXX financially healthy?
IDEXX LABORATORIES INC /DE's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does IDXX pay a dividend?
No, IDEXX LABORATORIES INC /DE does not currently pay a dividend.
How profitable is IDXX?
In FY2025, IDEXX LABORATORIES INC /DE had a net margin of 24.6% and a return on equity of 66.0%.
Is IDXX overvalued or undervalued?
IDEXX LABORATORIES INC /DE trades at about 43.6× trailing earnings — below its 10-year norm (10-year range 39.6×–71.3×, median 55.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for IDXX?
The average Wall-Street price target for IDEXX LABORATORIES INC /DE is $698.92, about 22.5% above the recent price, from 13 analysts (consensus: buy).
Is IDXX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IDEXX LABORATORIES INC /DE: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 41.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.